News >

Ivosidenib Shows Durable Disease Control in Advanced IDH1-Mutant Chondrosarcoma

Brittany Cote
Published: Friday, Apr 10, 2020

William D. Tap, MD from Memorial Sloan Kettering Cancer Center

William D. Tap, MD

Ivosidenib (Tibsovo) showed minimal toxicity, substantial 2-hydroxyglutarate (2-HG) reduction, and durable disease control in patients with chondrosarcoma, a rare primary malignancy of the bone, according to data from a phase I study.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication